Nasdaq · Healthcare
LEMAITRE VASCULAR INC (LMAT)
As-reported financials and recent SEC filings for LEMAITRE VASCULAR INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$249.6M
Net income
$57.7M
Net margin
23.1%
Diluted EPS
$2.52
ROE
14.7%
P/E (TTM)
35.2×
Market cap
$2.19B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $249.6M | $219.9M | $193.5M | $161.7M | $154.4M |
| Gross profit | $178.5M | $150.9M | $127.0M | $104.9M | $101.4M |
| Operating income | $67.9M | $52.3M | $36.7M | $26.8M | $36.4M |
| Net income | $57.7M | $44.0M | $30.1M | $20.6M | $26.9M |
| Diluted EPS | $2.52 | $1.93 | $1.34 | $0.93 | $1.25 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →Go deeper on LMAT
Search LEMAITRE VASCULAR INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.